{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:05:22Z","timestamp":1787879122740,"version":"build-2784847793"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2021-JX-0186-20"],"award-info":[{"award-number":["KC2021-JX-0186-20"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]},{"name":"ShanDong Provincial Medical Association","award":["No.YXH2022ZX02028"],"award-info":[{"award-number":["No.YXH2022ZX02028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06091-3","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:42:24Z","timestamp":1738813344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Small cell lung cancer with EML4-ALK fusion: report of a case responding to ALK TKI and literature review"],"prefix":"10.1007","volume":"151","author":[{"given":"Mingyue","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangling","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"4","key":"6091_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.chest.2020.04.068","volume":"158","author":"T Anish","year":"2020","unstructured":"Anish T, Idrees M, Camille T et al (2020) Clinical and genomic characteristics of small cell lung cancer in never smokers. Chest 158(4):1723\u20131733","journal-title":"Chest"},{"key":"6091_CR2","doi-asserted-by":"crossref","unstructured":"Cardona Andr\u00e9s F., Rojas L, Zatarain-Barr\u00f3n Zyanya L, et al. (2019) Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP). Front Oncol 9","DOI":"10.3389\/fonc.2019.00254"},{"key":"6091_CR3","first-page":"2","volume":"5","author":"A Charu","year":"2019","unstructured":"Charu A, Thompson JC, Black TA et al (2019) Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol 5:2","journal-title":"JAMA Oncol"},{"issue":"1","key":"6091_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/his.13842","volume":"75","author":"K Chiaki","year":"2019","unstructured":"Chiaki K, Yoshitsugu H, Yuko H et al (2019) Anaplastic lymphoma kinase expression in small-cell lung cancer. Histopathology 75(1):20\u201328","journal-title":"Histopathology"},{"issue":"3","key":"6091_CR5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.lungcan.2013.05.022","volume":"81","author":"T Gouji","year":"2013","unstructured":"Gouji T, Mitsuhiro T, Kenichi T et al (2013) An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene. Lung Cancer 81(3):487\u2013490","journal-title":"Lung Cancer"},{"issue":"3","key":"6091_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.21037\/tlcr-23-154","volume":"12","author":"X Guohao","year":"2023","unstructured":"Guohao X, Jiayuan H, Jie Ni et al (2023) Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report. Translat Lung Cancer Res 12(3):637\u2013646","journal-title":"Translat Lung Cancer Res"},{"key":"6091_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg B, Palmer RH (2016) The role of the ALK receptor in cancer biology. Ann Oncol 27:4\u201315","journal-title":"Ann Oncol"},{"key":"6091_CR8","doi-asserted-by":"crossref","unstructured":"Ou Sai-Hong I, Lee Alexandria T. M., Nagasaka M (2023) From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC. Crit Rev Oncol\/Hematol 187","DOI":"10.1016\/j.critrevonc.2023.104019"},{"key":"6091_CR9","doi-asserted-by":"crossref","unstructured":"Imyanitov Evgeny N, Iyevleva Aglaya G, Levchenko Evgeny V (2021) Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Crit Rev Oncol\/Hematol 157","DOI":"10.1016\/j.critrevonc.2020.103194"},{"issue":"6","key":"6091_CR10","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1158\/0008-5472.CAN-18-1082","volume":"79","author":"P Jillian","year":"2019","unstructured":"Jillian P, Alessandro L, Woodward BD et al (2019) Early noninvasive detection of response to targeted therapy in non-small cell lung cancer. Cancer Res 79(6):1204\u20131213","journal-title":"Cancer Res"},{"issue":"7563","key":"6091_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","volume":"524","author":"G Julie","year":"2015","unstructured":"Julie G, Shan LJ, Jin JS et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524(7563):47\u201353","journal-title":"Nature"},{"key":"6091_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3892\/ol.2022.13397","volume":"24","author":"Y Lei","year":"2022","unstructured":"Lei Y, Yan L, Xiang S et al (2022) EML4-ALK fusion gene in non-small cell lung cancer (Review). Oncol Lett 24:2","journal-title":"Oncol Lett"},{"key":"6091_CR13","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2019.11.002","volume":"139","author":"T Li","year":"2020","unstructured":"Li T, Zhang F, Zhaozhen W et al (2020) PLEKHM2-ALK: a novel fusion in small-cell lung cancer and durable response to ALK inhibitors. Lung Cancer 139:146\u2013150","journal-title":"Lung Cancer"},{"issue":"7153","key":"6091_CR14","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"S Manabu","year":"2007","unstructured":"Manabu S, Lim CY, Munehiro E et al (2007) Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561\u2013566","journal-title":"Nature"},{"key":"6091_CR15","doi-asserted-by":"crossref","unstructured":"Lim M, Murga-Zamalloa C (2014) ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmacogen Person Med","DOI":"10.2147\/PGPM.S37504"},{"issue":"28","key":"6091_CR16","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Moss\u00e9","year":"2017","unstructured":"Moss\u00e9 YP, Voss SD, Lim MS et al (2017) Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children\u2019s oncology group study. J Clin Oncol 35(28):3215\u20133221","journal-title":"J Clin Oncol"},{"issue":"6","key":"6091_CR17","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","volume":"29","author":"S Novello","year":"2018","unstructured":"Novello S, Mazi\u00e8res J, Oh I-J et al (2018) Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol off J Eur Soc Med Oncol 29(6):1409\u20131416","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"issue":"7","key":"6091_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","volume":"43","author":"MG Oser","year":"2024","unstructured":"Oser MG, David M, Oliver TG et al (2024) Genetically-engineered mouse models of small cell lung cancer: the next generation. Oncogene 43(7):457\u2013469","journal-title":"Oncogene"},{"issue":"5","key":"6091_CR19","first-page":"291","volume":"3","author":"HH Popper","year":"2014","unstructured":"Popper HH, Ryska A, T\u00edm\u00e1r J et al (2014) Molecular testing in lung cancer in the era of precision medicine. Transl Lung Cancer Res 3(5):291\u2013300","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"6091_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jtho.2022.10.002","volume":"18","author":"W Qian","year":"2023","unstructured":"Qian W, G\u00fcm\u00fc\u015f ZH, Cristina C et al (2023) SCLC: epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection. J Thor Oncol 18(1):31\u201346","journal-title":"J Thor Oncol"},{"issue":"1","key":"6091_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","volume":"8","author":"C Roberto","year":"2008","unstructured":"Roberto C, Claudia V, Chiara A et al (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 8(1):11\u201323","journal-title":"Nat Rev Cancer"},{"key":"6091_CR22","first-page":"14","volume":"14","author":"P Savvas","year":"2022","unstructured":"Savvas P, Pashley SL, Laura O et al (2022) Alternative treatment options to ALK inhibitor monotherapy for EML4-ALK-driven lung cancer. Cancers 14:14","journal-title":"Cancers"},{"issue":"6","key":"6091_CR23","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1016\/j.cllc.2021.03.012","volume":"22","author":"Q Shen","year":"2021","unstructured":"Shen Q, Kalyani FS, Jingjing Q et al (2021) A case of small cell lung carcinoma harboring an EML4\u2013ALK fusion with partial response to crizotinib. Clin Lung Cancer 22(6):e799\u2013e803","journal-title":"Clin Lung Cancer"},{"issue":"20","key":"6091_CR24","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1158\/1078-0432.CCR-19-0879","volume":"25","author":"D Siddhartha","year":"2019","unstructured":"Siddhartha D, Sumithra S, Herzog BH et al (2019) Circulating tumor DNA profiling in small-cell lung cancer identifies potentially targetable alterations. Clin Cancer Res 25(20):6119\u20136126","journal-title":"Clin Cancer Res"},{"key":"6091_CR25","doi-asserted-by":"publisher","first-page":"5161","DOI":"10.2147\/OTT.S323700","volume":"14","author":"N Sun","year":"2021","unstructured":"Sun N, Zhuang Y, Junling Z et al (2021) ALK rearrangement in small-cell lung cancer and durable response to alectinib: a case report. OncoTargets Therapy 14:5161\u20135166","journal-title":"OncoTargets Therapy"},{"issue":"4","key":"6091_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.6004\/jnccn.2022.7089","volume":"21","author":"MG Taylor","year":"2023","unstructured":"Taylor MG, Tao W, Robinson Andrew G (2023) Small cell lung cancer in light\/never smokers: a role for molecular testing? J Nat Compreh Cancer Network 21(4):336\u2013339","journal-title":"J Nat Compreh Cancer Network"},{"issue":"6","key":"6091_CR27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jtho.2024.01.013","volume":"19","author":"S Yuankai","year":"2024","unstructured":"Yuankai S, Jianhua C, Runxiang Y et al (2024) Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, phase 3 study (INSPIRE). J Thorac Oncol 19(6):912\u2013927","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06091-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06091-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T21:24:14Z","timestamp":1741814654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06091-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["6091"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06091-3","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted according to the Declaration of Helsinki and approved by Ethics Committee of Binzhou Medical University Hospital (Approval number is not applicable). Informed consent waiver with Ethics Committee of Binzhou Medical University Hospital that waived the need for informed consent because of the retrospective nature of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"62"}}